In tRCC harboring a 17 q gain and TFE3 fusion, a combination of cabozantinib with ipilimumab may yield desirable responses. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.